Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2026)
Janux Therapeutics (JANX) reported Depreciation & Amortization (CF) of $469000.0 for Q1 2026, down 9.63% year-over-year from $519000.0 in Q1 2025, and little changed quarter-over-quarter from $468000.0 in Q4 2025.
Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $469000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $469000.0, down 9.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 3.32% YoY), and the FY2025 annual result was $2.0 million, down 1.5% from the prior year.
- Depreciation & Amortization (CF) was little changed at $469000.0 in Q1 2026 per JANX's latest filing, from $468000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $541000.0 in Q2 2025 and troughed at $81000.0 in Q1 2022.
- A 5-year average of $432588.2 and a median of $500000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 822.22% in 2022, then dropped 9.63% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $403000.0 in 2022, then jumped by 31.76% to $531000.0 in 2023, then fell by 3.58% to $512000.0 in 2024, then fell by 8.59% to $468000.0 in 2025, then climbed by 0.21% to $469000.0 in 2026.
- Business Quant data shows JANX's Depreciation & Amortization (CF) at $469000.0 in Q1 2026, $468000.0 in Q4 2025, and $501000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | 469,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469,000.00 |
| Mar 31, 2026 | 469,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Dec 31, 2023 | 531,000.00 |
| Dec 31, 2023 | 531,000.00 |